Huan Yan, Lianxi Song, Yizhi Li, Qinqin Xu, Wenhuan Guo, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Li Deng, Zhe Huang, Haoyue Qin, Xing Zhang, Fan Tong, Ruiguang Zhang, Zhaoyi Liu, Lin Zhang, Juan Yu, Xiaorong Dong, Qian Gong, Jun Deng, Xue Chen, Jing Wang, Gao Zhang, Nong Yang, Yongchang Zhang, Liang Zeng
BACKGROUND: Pembrolizumab has been indicated in the treatment of solid tumors with high frequency microsatellite instability (MSI-H) or high tumor mutational burden (TMB-H); however, real-world data on the effectiveness of pembrolizumab with or without chemotherapy in this molecular subset remain limited. Our retrospective study evaluated the clinical efficacy and safety of pembrolizumab in treating advanced solid tumors with either MSI-H or TMB-H. METHODS: This retrospective study analyzed data from 116 patients with MSI-H or TMB-H advanced solid cancers who received pembrolizumab with or without chemotherapy regardless of treatment setting...
March 7, 2024: Cancer Immunology, Immunotherapy: CII